N6, N6-Dimethyladenosine

N6, N6-Dimethyladenosine, a modified ribonucleoside, is an endogenous A3 adenosine receptor ligand. N6, N6-Dimethyladenosine is an AKT inhibitor with antitumor effects. N6, N6-Dimethyladenosine targets SARS-CoV-2 entry protein ADAM17. N6, N6-Dimethyladenosine robustly inhibits AKT signaling in a variety of non-small cell lung cancer cell lines[1][2].

Product Specifications

CAS Number

[2620-62-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Adenosine Receptor; Akt; Nucleoside Antimetabolite/Analog; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage; GPCR/G Protein; PI3K/Akt/mTOR

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/N6,N6-Dimethyladenosine.html

Purity

99.95

Solubility

DMSO : ≥ 125 mg/mL

Smiles

O[C@H]1[C@@H](O)[C@H](N2C(N=CN=C3N(C)C)=C3N=C2)O[C@@H]1CO

Molecular Formula

C12H17N5O4

Molecular Weight

295.29

Precautions

H302, H315, H319, H335

References & Citations

[1]He J, et al. Antiviral Potential of Small Molecules Cordycepin, Thymoquinone, and N6, N6-Dimethyladenosine Targeting SARS-CoV-2 Entry Protein ADAM17. Molecules. 2022 Dec 19;27 (24) :9044. |[2]Vaden RM, et al. FUSION-Guided Hypothesis Development Leads to the Identification of N⁶, N⁶-Dimethyladenosine, a Marine-Derived AKT Pathway Inhibitor. Mar Drugs. 2017 Mar 15;15 (3) :75.